176 related articles for article (PubMed ID: 37140748)
1. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
Calthorpe L; Romero-Hernandez F; Casey M; Nunez M; Conroy PC; Hirose K; Kim A; Kirkwood K; Maker AV; Corvera C; Nakakura E; Alseidi A; Adam MA
Ann Surg Oncol; 2023 Aug; 30(8):5119-5129. PubMed ID: 37140748
[TBL] [Abstract][Full Text] [Related]
2. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
4. Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.
Valenzuela CD; Solsky IB; Erali RA; Forsythe SD; Mangieri CW; Mainali BB; Russell G; Perry KC; Votanopoulos KI; Shen P; Levine EA
Ann Surg Oncol; 2023 May; 30(5):2666-2675. PubMed ID: 36754945
[TBL] [Abstract][Full Text] [Related]
5. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
6. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
[TBL] [Abstract][Full Text] [Related]
7. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
[TBL] [Abstract][Full Text] [Related]
8. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
[TBL] [Abstract][Full Text] [Related]
9. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
[TBL] [Abstract][Full Text] [Related]
12. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
Magge D; Zenati MS; Austin F; Mavanur A; Sathaiah M; Ramalingam L; Jones H; Zureikat AH; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2014 Apr; 21(4):1159-65. PubMed ID: 24322529
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
Deban M; Taqi K; Knapp GC; Soucisse M; Curry M; Sidéris L; Dubé P; Khaldi MA; Jedrzejko N; Porter G; Giacomantonio C; Hamilton T; MacNeill A; Mack L; Bouchard-Fortier A
J Surg Oncol; 2023 Sep; 128(4):595-603. PubMed ID: 37249154
[TBL] [Abstract][Full Text] [Related]
14. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
[TBL] [Abstract][Full Text] [Related]
15. Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC.
Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
Ann Surg Oncol; 2024 Jan; 31(1):556-566. PubMed ID: 37940804
[TBL] [Abstract][Full Text] [Related]
16. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
17. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
[TBL] [Abstract][Full Text] [Related]
18. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.
Le Roy F; Gelli M; Hollebecque A; Honoré C; Boige V; Dartigues P; Benhaim L; Malka D; Ducreux M; Elias D; Goéré D
Ann Surg Oncol; 2017 Nov; 24(12):3640-3646. PubMed ID: 28849389
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up.
Malekzadeh P; Good M; Hughes MS
Int J Hyperthermia; 2021; 38(1):326-331. PubMed ID: 34139940
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.
Helm JH; Miura JT; Glenn JA; Marcus RK; Larrieux G; Jayakrishnan TT; Donahue AE; Gamblin TC; Turaga KK; Johnston FM
Ann Surg Oncol; 2015 May; 22(5):1686-93. PubMed ID: 25124472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
